{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:39:02Z","timestamp":1791517142444,"version":"4.3.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1038\/s41375-025-02666-8","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T08:59:42Z","timestamp":1750841982000},"page":"1883-1891","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes"],"prefix":"10.1038","volume":"39","author":[{"given":"Sara","family":"Pepe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2592-8724","authenticated-orcid":false,"given":"Candida","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Giannarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0271-7200","authenticated-orcid":false,"given":"Andrea","family":"Visentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Sanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Frustaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Olivieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4347-3775","authenticated-orcid":false,"given":"Francesca Maria","family":"Quaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0769-6891","authenticated-orcid":false,"given":"Alessandro","family":"Gozzetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5630-9862","authenticated-orcid":false,"given":"Paolo","family":"Sportoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Murru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idanna","family":"Innocenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Reda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livio","family":"Pupo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Levato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika","family":"Porrazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorella","family":"Ilariucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Moia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Foglietta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8370-5190","authenticated-orcid":false,"given":"Gian Matteo","family":"Rigolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Chiurazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6929-0729","authenticated-orcid":false,"given":"Fabio","family":"Trastulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Cellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Deodato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Laurenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Coscia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cuneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4681-0151","authenticated-orcid":false,"given":"Gianluca","family":"Gaidano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2425-9474","authenticated-orcid":false,"given":"Francesca R.","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"key":"2666_CR1","first-page":"285","volume":"4","author":"MN Richter","year":"1928","unstructured":"Richter MN. Generalized reticular cell sarcoma of lymph nodes associated with lymphatic leukemia. Am J Pathol. 1928;4:285\u201392.","journal-title":"Am J Pathol"},{"key":"2666_CR2","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/bjh.12458","volume":"162","author":"SA Parikh","year":"2013","unstructured":"Parikh SA, Rabe KG, Call TG, Zent CS, Habermann TM, Ding W, et al. Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. Br J Haematol. 2013;162:774\u201382.","journal-title":"Br J Haematol"},{"key":"2666_CR3","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s11899-014-0223-4","volume":"9","author":"SA Parikh","year":"2014","unstructured":"Parikh SA, Shanafelt TD. Risk factors for Richter syndrome in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2014;9:294\u20139.","journal-title":"Curr Hematol Malig Rep"},{"key":"2666_CR4","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1080\/10428194.2020.1719092","volume":"61","author":"Y Ben-Dali","year":"2020","unstructured":"Ben-Dali Y, Hleuhel MH, da Cunha-Bang C, Brieghel C, Poulsen CB, Clasen-Linde E, et al. Richter\u2019s transformation in patients with chronic lymphocytic leukaemia: a Nationwide Epidemiological Study. Leuk Lymphoma. 2020;61:1435\u201344.","journal-title":"Leuk Lymphoma"},{"key":"2666_CR5","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1007\/s00277-021-04603-y","volume":"100","author":"R Elnair","year":"2021","unstructured":"Elnair R, Ellithi M, Kallam A, Shostrom V, Bociek RG. Outcomes of Richter\u2019s transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): an analysis of the SEER database. Ann Hematol. 2021;100:2513\u20139.","journal-title":"Ann Hematol"},{"key":"2666_CR6","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/ajh.24714","volume":"92","author":"FR Mauro","year":"2017","unstructured":"Mauro FR, Galieni P, Tedeschi A, Laurenti L, Del Poeta G, Reda G, et al. Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma. Am J Hematol. 2017;92:529\u201335.","journal-title":"Am J Hematol"},{"key":"2666_CR7","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bjh.18241","volume":"198","author":"K Zhu","year":"2022","unstructured":"Zhu K, Jamroz A, Huang S, Villa D, Freeman CL, Scott DW, et al. Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British Columbia. Br J Haematol. 2022;198:684\u201392.","journal-title":"Br J Haematol"},{"key":"2666_CR8","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375\u201390.","journal-title":"Blood"},{"key":"2666_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.829983","volume":"12","author":"A Condoluci","year":"2022","unstructured":"Condoluci A, Rossi D. Biology and treatment of Richter transformation. Front Oncol. 2022;12:829983.","journal-title":"Front Oncol"},{"key":"2666_CR10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2023-190077","volume":"142","author":"EM Parry","year":"2023","unstructured":"Parry EM, Ten Hacken E, Wu CJ. Richter syndrome: novel insights into the biology of transformation. Blood. 2023;142:11\u201322.","journal-title":"Blood"},{"key":"2666_CR11","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3324\/haematol.2021.278304","volume":"107","author":"A Visentin","year":"2022","unstructured":"Visentin A, Bonaldi L, Rigolin GM, Mauro FR, Martines A, Frezzato F, et al. The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation. Haematologica. 2022;107:868\u201376.","journal-title":"Haematologica"},{"key":"2666_CR12","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","volume":"117","author":"D Rossi","year":"2011","unstructured":"Rossi D, Spina V, Deambrogi C, Rasi S, Laurenti L, Stamatopoulos K, et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood. 2011;117:3391\u2013401. 24.","journal-title":"Blood"},{"key":"2666_CR13","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1182\/blood-2011-09-379966","volume":"119","author":"D Rossi","year":"2012","unstructured":"Rossi D, Rasi S, Fabbri G, Spina V, Fangazio M, Forconi F, et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood. 2012;119:521\u20139.","journal-title":"Blood"},{"key":"2666_CR14","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/leu.2012.357","volume":"27","author":"N Villamor","year":"2013","unstructured":"Villamor N, Conde L, Mart\u00ednez-Trillos A, Cazorla M, Navarro A, Be\u00e0 S, et al. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia. 2013;27:1100\u20136.","journal-title":"Leukemia"},{"key":"2666_CR15","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1182\/blood-2013-03-489518","volume":"122","author":"E Chigrinova","year":"2013","unstructured":"Chigrinova E, Rinaldi A, Kwee I, Rossi D, Rancoita PMV, Strefford JC, et al. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood. 2013;122:2673\u201382.","journal-title":"Blood"},{"key":"2666_CR16","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1084\/jem.20131448","volume":"210","author":"G Fabbri","year":"2013","unstructured":"Fabbri G, Khiabanian H, Holmes AB, Wang J, Messina M, Mullighan CG, et al. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J Exp Med. 2013;210:2273\u201388.","journal-title":"J Exp Med"},{"key":"2666_CR17","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41591-022-02113-6","volume":"29","author":"EM Parry","year":"2023","unstructured":"Parry EM, Leshchiner I, Gui\u00e8ze R, Johnson C, Tausch E, Parikh SA, et al. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. Nat Med. 2023;29:158\u201369.","journal-title":"Nat Med"},{"key":"2666_CR18","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1038\/s41591-022-01927-8","volume":"28","author":"F Nadeu","year":"2022","unstructured":"Nadeu F, Royo R, Massoni-Badosa R, Playa-Albinyana H, Garcia-Torre B, Duran-Ferrer M, et al. Detection of early seeding of Richter transformation in chronic lymphocytic leukemia. Nat Med. 2022;28:1662\u201371.","journal-title":"Nat Med"},{"key":"2666_CR19","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-08-3266","volume":"15","author":"D Rossi","year":"2009","unstructured":"Rossi D, Spina V, Cerri M, Rasi S, Deambrogi C, De Paoli L, et al. Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. Clin Cancer Res. 2009;15:4415\u201322.","journal-title":"Clin Cancer Res"},{"key":"2666_CR20","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1097\/PAS.0b013e31804bdaf8","volume":"31","author":"Z Mao","year":"2007","unstructured":"Mao Z, Quintanilla-Martinez L, Raffeld M, Richter M, Krugmann J, Burek C, et al. IgVH mutational status and clonality analysis of Richter\u2019s transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution. Am J Surg Pathol. 2007;31:1605\u201314.","journal-title":"Am J Surg Pathol"},{"key":"2666_CR21","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1182\/blood-2013-11-536169","volume":"123","author":"L Falchi","year":"2014","unstructured":"Falchi L, Keating MJ, Marom EM, Truong MT, Schlette EJ, Sargent RL, et al. Correlation between FDG\/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood. 2014;123:2783\u201390.","journal-title":"Blood"},{"key":"2666_CR22","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.3109\/10428194.2015.1099643","volume":"57","author":"AS Michallet","year":"2016","unstructured":"Michallet AS, Sesques P, Rabe KG, Itti E, Tordot J, Tychyj-Pinel C, et al. An 18F-FDG-PET maximum standardized uptake value > 10 represents a novel valid marker for discerning Richter\u2019s Syndrome. Leuk Lymphoma. 2016;57:1474\u20137.","journal-title":"Leuk Lymphoma"},{"key":"2666_CR23","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1038\/leu.2015.21","volume":"29","author":"FR Mauro","year":"2015","unstructured":"Mauro FR, Chauvie S, Paoloni F, Biggi A, Cimino G, Rago A, et al. Diagnostic and prognostic role of PET\/CT in patients with chronic lymphocytic leukemia and progressive disease. Leukemia. 2015;29:1360\u20135.","journal-title":"Leukemia"},{"key":"2666_CR24","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.3324\/haematol.2018.207068","volume":"104","author":"AR Mato","year":"2019","unstructured":"Mato AR, Wierda WG, Davids MS, Cheson BD, Coutre SE, Choi M, et al. Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy. Haematologica. 2019;104:2258\u201364.","journal-title":"Haematologica"},{"key":"2666_CR25","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.3390\/cancers12071773","volume":"12","author":"M Porrazzo","year":"2020","unstructured":"Porrazzo M, Nicolai E, Riminucci M, Vitale C, Coscia M, De Paoli L, et al. Prognostic significance of PET\/CT in patients with chronic lymphocytic leukemia (CLL) treated with front-line chemoimmunotherapy. Cancers. 2020;12:1773.","journal-title":"Cancers"},{"key":"2666_CR26","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.3324\/haematol.2019.240564","volume":"105","author":"Y Wang","year":"2020","unstructured":"Wang Y, Rabe KG, Bold MS, Shi M, Hanson CA, Schwager SM, et al. The role of 18F-FDG-PET in detecting Richter\u2019s transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor. Haematologica. 2020;105:2675\u20138.","journal-title":"Haematologica"},{"key":"2666_CR27","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","volume":"1","author":"KJ Maddocks","year":"2015","unstructured":"Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015;1:80\u20137.","journal-title":"JAMA Oncol"},{"key":"2666_CR28","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1002\/cncr.30596","volume":"123","author":"P Jain","year":"2017","unstructured":"Jain P, Thompson PA, Keating M, Estrov Z, Ferrajoli A, Jain N, et al. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer. 2017;123:2268\u201373.","journal-title":"Cancer"},{"key":"2666_CR29","doi-asserted-by":"publisher","first-page":"7505","DOI":"10.1200\/JCO.2017.35.15_suppl.7505","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, Huang Y, Rogers KA, Stern R, Brown JR, Thompson PA, et al. Richter\u2019s syndrome (RS) in patients with chronic lymphocytic leukemia (CLL) on novel agent therapy [abstract]. JCO. 2017;35:7505\u20137505.","journal-title":"JCO"},{"key":"2666_CR30","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/bjh.16748","volume":"190","author":"P Abrisqueta","year":"2020","unstructured":"Abrisqueta P, Delgado J, Alcoceba M, Oliveira AC, Loscertales J, Hern\u00e1ndez-Rivas JA, et al. Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC). Br J Haematol. 2020;190:854\u201363.","journal-title":"Br J Haematol"},{"key":"2666_CR31","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3324\/haematol.2019.224121","volume":"105","author":"Y Wang","year":"2020","unstructured":"Wang Y, Tschautscher MA, Rabe KG, Call TG, Leis JF, Kenderian SS, et al. Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. Haematologica. 2020;105:765\u201373.","journal-title":"Haematologica"},{"key":"2666_CR32","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/ajh.26755","volume":"98","author":"AS Kittai","year":"2023","unstructured":"Kittai AS, Huang Y, Beckwith KA, Bhat SA, Bond DA, Byrd JC, et al. Patient characteristics that predict Richter\u2019s transformation in patients with chronic lymphocytic leukemia treated with ibrutinib. Am J Hematol. 2023;98:56\u201365.","journal-title":"Am J Hematol"},{"key":"2666_CR33","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745\u201360.","journal-title":"Blood"},{"key":"2666_CR34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41375-020-0797-x","volume":"35","author":"O Al-Sawaf","year":"2021","unstructured":"Al-Sawaf O, Robrecht S, Bahlo J, Fink AM, Cramer P, V Tresckow J, et al. Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials. Leukemia. 2021;35:169\u201376.","journal-title":"Leukemia"},{"key":"2666_CR35","unstructured":"Hampel PJ, Rabe KG, Wang Y, Hwang SR, Kenderian SS, Muchtar E, et al. Incidence of Richter transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma in the targeted therapy era. Leukemia. 2024; Epub ahead of print. https:\/\/www.nature.com\/articles\/s41375-024-02492-4"},{"key":"2666_CR36","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","volume":"125","author":"P Jain","year":"2015","unstructured":"Jain P, Keating M, Wierda W, Estrov Z, Ferrajoli A, Jain N, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015;125:2062\u20137.","journal-title":"Blood"},{"key":"2666_CR37","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","volume":"125","author":"JC Byrd","year":"2015","unstructured":"Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, et al. Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125:2497\u2013506.","journal-title":"Blood"},{"key":"2666_CR38","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1182\/blood-2017-12-820910","volume":"131","author":"IE Ahn","year":"2018","unstructured":"Ahn IE, Farooqui MZH, Tian X, Valdez J, Sun C, Soto S, et al. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. Blood. 2018;131:2357\u201366.","journal-title":"Blood"},{"key":"2666_CR39","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/bjh.17882","volume":"196","author":"TA Eyre","year":"2022","unstructured":"Eyre TA, Riches JC, Patten PEM, Walewska R, Marr H, Follows G, et al. Richter transformation of chronic lymphocytic leukaemia: a British Society for Haematology Good Practice Paper. Br J Haematol. 2022;196:864\u201370.","journal-title":"Br J Haematol"},{"key":"2666_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101163","volume":"64","author":"A Barrett","year":"2024","unstructured":"Barrett A, Appleby N, Dreau H, Fox CP, Munir T, Eyre TA. Richter\u2019s transformation: transforming the clinical landscape. Blood Rev. 2024;64:101163.","journal-title":"Blood Rev"},{"key":"2666_CR41","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1182\/bloodadvances.2016003632","volume":"1","author":"S Kadri","year":"2017","unstructured":"Kadri S, Lee J, Fitzpatrick C, Galanina N, Sukhanova M, Venkataraman G, et al. Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL. Blood Adv. 2017;1:715\u201327.","journal-title":"Blood Adv"},{"key":"2666_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102619","volume":"120","author":"P Abrisqueta","year":"2023","unstructured":"Abrisqueta P, Nadeu F, Bosch-Schips J, Iacoboni G, Serna A, Cabirta A, et al. From genetics to therapy: Unraveling the complexities of Richter transformation in chronic lymphocytic leukemia. Cancer Treat Rev. 2023;120:102619.","journal-title":"Cancer Treat Rev"},{"key":"2666_CR43","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1038\/leu.2016.113","volume":"30","author":"C Maurer","year":"2016","unstructured":"Maurer C, Langerbeins P, Bahlo J, Cramer P, Fink AM, Pflug N, et al. Effect of first-line treatment on second primary malignancies and Richter\u2019s transformation in patients with CLL. Leukemia. 2016;30:2019\u201325.","journal-title":"Leukemia"},{"key":"2666_CR44","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/hon.3164_343","volume":"41","author":"MS Davids","year":"2023","unstructured":"Davids MS, Rogers KA, Jain N, Tyekucheva S, Ren Y, Carey C, et al. Initial results of a multicenter phase 2 study of venetoclax in combination with R-CHOP (VR-CHOP) for patients with Richter Syndrome [abstract]. Hematol Oncol. 2023;41:466\u20138.","journal-title":"Hematol Oncol"},{"key":"2666_CR45","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1182\/bloodadvances.2023012080","volume":"8","author":"PJ Hampel","year":"2024","unstructured":"Hampel PJ, Swaminathan M, Rogers KA, Parry EM, Burger JA, Davids MS, et al. A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia. Blood Adv. 2024;8:2342\u201350.","journal-title":"Blood Adv"},{"key":"2666_CR46","doi-asserted-by":"publisher","first-page":"e682","DOI":"10.1016\/S2352-3026(24)00172-8","volume":"11","author":"WG Wierda","year":"2024","unstructured":"Wierda WG, Shah NN, Cheah CY, Lewis D, Hoffmann MS, Coombs CC, et al. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1\/2 BRUIN study. Lancet Haematol. 2024;11:e682\u201392.","journal-title":"Lancet Haematol"},{"key":"2666_CR47","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1182\/blood-2021-154279","volume":"138","author":"N Jain","year":"2021","unstructured":"Jain N, Ferrajoli A, Thompson PA, Konopleva M, Green MR, Sampath D, et al. Venetoclax, obinutuzumab and atezolizumab (PD-L1 checkpoint inhibitor) for treatment for patients with Richter transformation [abstract]. Blood. 2021;138:1550.","journal-title":"Blood"},{"key":"2666_CR48","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41591-023-02722-9","volume":"30","author":"O Al-Sawaf","year":"2024","unstructured":"Al-Sawaf O, Ligtvoet R, Robrecht S, Stumpf J, Fink AM, Tausch E, et al. Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial. Nat Med. 2024;30:240\u20138.","journal-title":"Nat Med"},{"key":"2666_CR49","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/S1470-2045(24)00396-6","volume":"25","author":"A Tedeschi","year":"2024","unstructured":"Tedeschi A, Frustaci AM, Condoluci A, Coscia M, Chiarle R, Zinzani PL, et al. Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2024;25:1298\u2013309.","journal-title":"Lancet Oncol"},{"key":"2666_CR50","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1182\/blood-2022-158298","volume":"140","author":"AP Kater","year":"2022","unstructured":"Kater AP, Ye JC, Sandoval-Sus J, Bellido M, Christensen JH, Mato AR, et al. Subcutaneous epcoritamab in patients with Richter\u2019s syndrome: early results from phase 1b\/2 trial (EPCORE CLL-1) [abstract]. Blood. 2022;140:850\u20131.","journal-title":"Blood"},{"key":"2666_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51264-2","volume":"15","author":"R Gui\u00e8ze","year":"2024","unstructured":"Gui\u00e8ze R, Ysebaert L, Roos-Weil D, Fornecker LM, Ferrant E, Molina L, et al. Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial. Nat Commun. 2024;15:6822.","journal-title":"Nat Commun"},{"key":"2666_CR52","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1038\/s41375-022-01649-3","volume":"36","author":"PA Thompson","year":"2022","unstructured":"Thompson PA, Jiang X, Banerjee P, Basar R, Garg N, Chen K, et al. A phase two study of high dose blinatumomab in Richter\u2019s syndrome. Leukemia. 2022;36:2228\u201332.","journal-title":"Leukemia"},{"key":"2666_CR53","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1200\/JCO.24.00033","volume":"42","author":"AS Kittai","year":"2024","unstructured":"Kittai AS, Bond D, Huang Y, Bhat SA, Blyth E, Byrd JC, et al. Anti-CD19 chimeric antigen receptor T-cell therapy for Richter transformation: an International, Multicenter, Retrospective Study. JCO. 2024;42:2071\u20139.","journal-title":"JCO"},{"key":"2666_CR54","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1111\/ejh.14182","volume":"112","author":"N Kutsch","year":"2024","unstructured":"Kutsch N, G\u00f6del P, Voltin C, Hallek M, Scheid C, Borchmann P, et al. Long-term remission in a patient with relapsed Richter\u2019s transformation treated with CD19-directed chimeric antigen-receptor T-cells after allogeneic stem cell transplantation. European J Haematol. 2024;112:984\u20137.","journal-title":"European J Haematol"},{"key":"2666_CR55","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/ajh.25638","volume":"94","author":"T Munir","year":"2019","unstructured":"Munir T, Brown JR, O\u2019Brien S, Barrientos JC, Barr PM, Reddy NM, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94:1353\u201363.","journal-title":"Am J Hematol"},{"key":"2666_CR56","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.3324\/haematol.2021.279012","volume":"107","author":"C Moreno","year":"2022","unstructured":"Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, et al. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. Haematologica. 2022;107:2108\u201320.","journal-title":"Haematologica"},{"key":"2666_CR57","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1182\/blood.2023021959","volume":"143","author":"JA Woyach","year":"2024","unstructured":"Woyach JA, Perez Burbano G, Ruppert AS, Miller C, Heerema NA, Zhao W, et al. Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL. Blood. 2024;143:1616\u201327.","journal-title":"Blood"},{"key":"2666_CR58","doi-asserted-by":"publisher","first-page":"5566","DOI":"10.1158\/1078-0432.CCR-21-0701","volume":"27","author":"R Bomben","year":"2021","unstructured":"Bomben R, Rossi FM, Vit F, Bittolo T, D\u2019Agaro T, Zucchetto A, et al. TP53 Mutations with low variant allele frequency predict short survival in chronic lymphocytic leukemia. Clin Cancer Res. 2021;27:5566\u201375.","journal-title":"Clin Cancer Res"},{"key":"2666_CR59","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.annonc.2024.06.016","volume":"35","author":"B Eichhorst","year":"2024","unstructured":"Eichhorst B, Ghia P, Niemann CU, Kater AP, Gregor M, Hallek M, et al. ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia. Ann Oncol. 2024;35:762\u20138.","journal-title":"Ann Oncol"},{"key":"2666_CR60","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1200\/JCO.2005.05.0187","volume":"24","author":"AM Tsimberidou","year":"2006","unstructured":"Tsimberidou AM, O\u2019Brien S, Khouri I, Giles FJ, Kantarjian HM, Champlin R, et al. Clinical outcomes and prognostic factors in patients with Richter\u2019s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol. 2006;24:2343\u201351.","journal-title":"J Clin Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02666-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02666-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02666-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T23:57:58Z","timestamp":1757203078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02666-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":60,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2666"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02666-8","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]},"assertion":[{"value":"9 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}